Dr. Miller’s exciting research in the field of neurodegenerative diseases consistently generates national and international excitement. 


Experimental Drug Shows Promise for Genetic Form of ALS

An early stage trial of an investigational therapy for amyotrophic lateral sclerosis (ALS) suggests that people could tolerate the experimental drug and, in exploratory results, the experimental drug was linked to possible slower progression in people with a genetic form of the disease caused by mutations in a gene called superoxide dismutase 1 (SOD1).

Scientists Reverse Alzheimer’s-Like Symptoms in Mice

Scientists Reverse Alzheimer’s-Like Symptoms in Mice
Engadget states, “Scientists have discovered a way of counteracting proteins that cause Alzheimer’s-like symptoms including memory loss. Researchers at Washington University in St. Louis, Missouri focus on tau protein tangles.” in an article about Dr. Miller’s 2017 STM publication.

Scientists Stop and Reverse Alzheimer’s-Related Brain Damage in Mice

A news release by MNT examines Dr. Miller’s 2017 STM publication. “The team studied the effects of the synthetic molecules on crab-eating macaques. They administered two doses of antisense oligonucleotides or two doses of a placebo, 1 week apart, directly into the cerebrospinal fluid – as one would when treating humans. The trial revealed that, in monkeys […]

Molecule Throws Roadblock in Alzheimer’s Path

Molecule Throws Roadblock in Alzheimer’s Path
An article by New Atlas describing Dr. Miller’s STM work states, “When it comes to the drama of Alzheimer’s disease, the compound in the starring role as the villain is tau. It’s a protein that normally helps our neurons function properly, but one that can clump together into plaques that damage brain cells. Now researchers have […]

Antisense Oligos Tango with Tau Transcripts to Reverse Tauopathy

Antisense Oligos Tango with Tau Transcripts to Reverse Tauopathy
In an article about Dr. Miller’s newest Science Translational Medicine publication, ALZFORUM writes, “In collaboration with the pharmaceutical company Ionis in Carlsbad, California, Timothy Miller and his colleagues at Washington University in St. Louis designed a potent ASO that shuts down human tau gene expression in transgenic mouse models.”

Publication by Mariah L. Hoye, PhD Candidate

Congratulations to Miller Lab member Mariah L. Hoye on her publication! Mariah is a PhD candidate who is studying microRNAs, which are small compounds that regulate a variety of processes in the body, and their role in ALS disease progression. Her manuscript that investigates microRNAs specific to motor neurons in ALS rodent models was recently […]

Publication by Kathleen Schoch, PhD

Congratulations to Miller Lab member Kathleen Schoch on her publication! Dr. Kathleen Schoch is a postdoctoral research assistant in the Miller Lab who focuses on dementias characterized by the pathological accumulation of the protein “tau”. She published a paper in Neuron that examined the potential of a unique tau-lowering therapeutic strategy to treat Alzheimer’s disease, […]